Review steps to develop programs to eradicate HCV in the U.S. at this program. Speakers will address the current state of screening, novel models to engage more patients into therapy and the current state of access to HCV therapeutics, including generics. They will contrast U.S. efforts to eradicate HCV with programs from around the world.
Recent advances in liver bio-engineering have led to multiple in vitro culture systems that duplicate many complex cell-cell interactions of the intact liver. This symposium will highlight recent advances in this field, show current use of ex-vivo, 3D multicellular culture systems as probes of liver function and disease and update the progress toward the generation of the bio-artificial liver.
The Career Development Workshop is designed for hepatologists in the early career stage. Participants will explore how to maximize career opportunities in basic and clinical research, and will discuss potential sources of research funding for each pathway. They will also review an array of career pathways in both academic and community practice, and possible rewards and challenges hepatologists may encounter.
Angela C. Cheung, Douglas I. Walker, Brian D. Juran, Gary W. Miller, Konstantinos N. Lazaridis – 8 November 2019
Naim Alkhouri, Rohit Kohli, Ariel E. Feldstein – 8 November 2019 – Nonalcoholic fatty liver disease (NAFLD) is common in children and may progress to nonalcoholic steatohepatitis (NASH), advanced fibrosis, and even cirrhosis in childhood or early adulthood, indicating the need for pharmacologic treatment in this age group. Multiple trials are evaluating different therapeutic targets for NASH with fibrosis in adults, and the U.S.
Brian P. Lee, Eric Vittinghoff, Mark J. Pletcher, Jennifer L. Dodge, Norah A. Terrault – 8 November 2019
Berangere Gapp, Marie Jourdain, Pauline Bringer, Benjamin Kueng, Delphine Weber, Arnaud Osmont, Stefan Zurbruegg, Judith Knehr, Rocco Falchetto, Guglielmo Roma, William Dietrich, Reginald Valdez, Nicolau Beckmann, Florian Nigsch, Arun J. Sanyal, Iwona Ksiazek – 8 November 2019 – A promising approach for the treatment of nonalcoholic steatohepatitis (NASH) is the inhibition of enhanced hepatic de novo lipogenesis (DNL), which is the synthesis of fatty acids from nonlipid sources.
Guohong Han, Sarah Berhane, Hidenori Toyoda, Dominik Bettinger, Omar Elshaarawy, Anthony W. H. Chan, Martha Kirstein, Cristina Mosconi, Florian Hucke, Daniel Palmer, David J. Pinato, Rohini Sharma, Diego Ottaviani, Jeong W. Jang, Tim A. Labeur, Otto M. Delden, Mario Pirisi, Nick Stern, Bruno Sangro, Tim Meyer, Waleed Fateen, Marta García‐Fiñana, Asmaa Gomaa, Imam Waked, Eman Rewisha, Guru P. Aithal, Simon Travis, Masatoshi Kudo, Alessandro Cucchetti, Markus Peck‐Radosavljevic, R.B. Takkenberg, Stephen L. Chan, Arndt Vogel, Philip J. Johnson – 7 November 2019
Enpeng Zhao, Yang Shen, Muhammad Amir, Alton B. Farris, Mark J. Czaja – 7 November 2019 – The endogenous cellular signals that initiate the transition of hepatocytes from quiescence to proliferation remain unclear. The protein stathmin 1 (STMN1) is highly expressed in dividing cells, including hepatocytes, and functions to promote cell mitosis through physical interactions with tubulin and microtubules that regulate mitotic spindle formation.
Ivana Carey, Jeffrey Gersch, Bo Wang, Christiana Moigboi, Mary Kuhns, Gavin Cloherty, Geoffrey Dusheiko, Kosh Agarwal – 7 November 2019